Skip to main content
. 2020 Jul 10;9:e55513. doi: 10.7554/eLife.55513

Figure 7. The cardiac benefit of SS-31 treatment is not additive to that of mCAT expression but the two interventions differentially regulate myofilament protein phosphorylation.

Figure 7.

(a) Diastolic function (Ea/Aa) improved at both 8 and 12 weeks after AAV9-mCAT administration. n = 3 (saline) and n = 5 (AAV-mCAT) female mice were analyzed by repeated measure ANOVA with Tukey’s multiple comparison test between time points and Sidak post hoc analysis between treatment groups. (b) 8-week SS-31 improved diastolic function in old WT but did not further improve the function of old mCAT mice; n = 5 (for SS-WT and SS-mCAT) and n = 6 (for Saline-WT) mixed-sex mice were analyzed by repeated measure ANOVA with Tukey’s multiple comparison test between time points. (c) Late-life mCAT expression reduced Ser282 phosphorylation of MyBP-C. (d–e) Late-life mCAT expression increased phosphorylation of cTnI at Ser23/24 (d) and Ser150 (e). For panel c-e, n = 3 and 5 female mice were used for saline and AAV-mCAT, respectively, and were analyzed by unpaired T-test.